:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Pharmacology
Online Access:	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.17469
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cellular forgetting, desensitisation, stress and aging in signalling networks. When do cells refuse to learn more?
by: Veres, Tamas, et al.
Published: (2023)

Natural products and cancer: From drug discovery to prevention and therapy
by: Angelo A. Izzo, et al.
Published: (2025)

The use of different types of networks, alone and in combination, for drug target identification
by: Paolo Parini
Published: (2025)

Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer
by: Rui Wang, et al.
Published: (2025)

Circumventing glioblastoma resistance to temozolomide through optimal drug combinations designed by systems pharmacology and machine learning
by: Sergio Corridore, et al.
Published: (2025)

P2X7 receptor antagonism suppresses epileptiform‐like activity in an inflammation‐primed human iPSC‐derived neuron model of drug‐resistant epilepsy
by: Jaideep Kesavan, et al.
Published: (2025)

Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome
by: Nazanin Pazhouhesh Far, et al.
Published: (2024)

EpigenPlot: An interactive web platform for DNA methylation‐based biomarker and drug target discovery in colorectal cancer
by: Dalma Müller, et al.
Published: (2025)

Credibility of genetic predictors for antiepileptic drug resistance: A systematic Bayesian reappraisal of published meta‐analyses
by: Martina Giacon, et al.
Published: (2025)

Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
Published: (2024)

Identification of prokineticin‐2 as potential pharmacodynamic biomarker for overcoming doxorubicin resistance in multicellular breast cancer spheroids
by: Martina Vincenzi, et al.
Published: (2025)

Identification of drug repurposing candidates for the treatment of polycystic kidney disease
by: Alina Meyer, et al.
Published: (2026)

Advancing antihypertensive drug development
by: Fay Pu, et al.
Published: (2025)

A deep neural network model for optimizing traditional Chinese medicine prescriptions with data augmentation
by: Xiaohan Mao, et al.
Published: (2025)

Oseltamivir drug‐disease modelling in infants with influenza virus infection
by: Kun Wang, et al.
Published: (2026)

RETRACTED: Effects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial
by: Juan Carlos Yugar‐Toledo, et al.
Published: (2025)

Evaluating the capability of ChatGPT in predicting drug–drug interactions: Real‐world evidence using hospitalized patient data
by: Ramya Padmavathy Radha Krishnan, et al.
Published: (2024)

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women
by: William Saffaf, et al.
Published: (2026)

Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
by: Adrian Steulet, et al.
Published: (2024)

The impact of pretreatment drug resistance on ainuovirine‐based antiviral therapy in HIV‐infected patients: A subgroup analysis from the RACER study
by: Q. Li, et al.
Published: (2025)

Opportunities of patient‐derived organoids in drug development
by: Antonia Büning, et al.
Published: (2025)

Genetic polymorphisms influencing antihypertensive drug responses
by: Jana El Cheikh, et al.
Published: (2024)

Chemistry/structural biology of psychedelic drugs and their receptor(s)
by: Ryan H. Gumpper, et al.
Published: (2024)

Emerging therapeutic opportunities for psychedelic and related drugs
by: Susan Wonnacott, et al.
Published: (2026)

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
by: Stavros Topouzis, et al.
Published: (2025)

Correction to “Genetic polymorphisms influencing antihypertensive drug responses”
Published: (2025)

The eyes of the beholder: Perceived barriers to successful drug repurposing
by: Zsuzsanna Ida Petykó, et al.
Published: (2025)

Exploring drug mechanisms through single‐cell proteomics
by: Yuzhi Sun, et al.
Published: (2026)

Quantification of cure for pharmacodynamic models of antimalarial drugs: Deterministic versus stochastic approaches
by: Meg K. Tully, et al.
Published: (2025)

External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
by: Dominic M. Alfonso, et al.
Published: (2026)

Experience of a nirmatrelvir/ritonavir drug–drug interaction expert advice service
Published: (2024)

A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
by: Jane Knöchel, et al.
Published: (2024)

A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs
by: Tara Suchak, et al.
Published: (2024)

Common pitfalls in oncology drug applications aiming for conditional marketing authorization
by: Sinan B. Sarac, et al.
Published: (2025)

Artificial intelligence streamlines scientific discovery of drug–target interactions
by: Yuxin Yang, et al.
Published: (2025)

Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib
by: Bennet Y. Weber, et al.
Published: (2025)

Have plastic culture models prevented the discovery of effective cancer therapeutics?
by: Kevin M. Tharp
Published: (2024)

Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study
by: Amelie Leutzendorff, et al.
Published: (2024)

Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties
by: Geofrey Oteng Phutietsile, et al.
Published: (2024)

Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response
by: Magnus Ingelman‐Sundberg, et al.
Published: (2024)